These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 28798070)

  • 1. CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinib.
    Vos JM; Tsakmaklis N; Patterson CJ; Meid K; Castillo JJ; Brodsky P; Ganz T; Pals ST; Kersten MJ; Xu L; Yang G; Treon SP; Hunter ZR
    Haematologica; 2017 Nov; 102(11):e452-e455. PubMed ID: 28798070
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of ibrutinib in the treatment of Bing-Neel syndrome.
    Cabannes-Hamy A; Lemal R; Goldwirt L; Poulain S; Amorim S; Pérignon R; Berger J; Brice P; De Kerviler E; Bay JO; Sauvageon H; Beldjord K; Mourah S; Tournilhac O; Thieblemont C
    Am J Hematol; 2016 Mar; 91(3):E17-9. PubMed ID: 26689870
    [No Abstract]   [Full Text] [Related]  

  • 3. Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM rebound.
    Gustine JN; Meid K; Dubeau T; Severns P; Hunter ZR; Guang Y; Xu L; Treon SP; Castillo JJ
    Am J Hematol; 2018 Aug; 93(4):511-517. PubMed ID: 29280186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resolution of Waldenström Macroglobulinemia-Associated Autoimmune Hemolysis With Ibrutinib.
    Tripathi A; Steingart R
    J Oncol Pract; 2016 May; 12(5):490-1. PubMed ID: 27170696
    [No Abstract]   [Full Text] [Related]  

  • 5. Ibrutinib in the management of Waldenstrom macroglobulinemia.
    Yosef A; Touloukian EZ; Nambudiri VE
    J Oncol Pharm Pract; 2019 Mar; 25(2):434-441. PubMed ID: 29996737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ibrutinib in previously treated Waldenström's macroglobulinemia.
    Treon SP; Tripsas CK; Meid K; Warren D; Varma G; Green R; Argyropoulos KV; Yang G; Cao Y; Xu L; Patterson CJ; Rodig S; Zehnder JL; Aster JC; Harris NL; Kanan S; Ghobrial I; Castillo JJ; Laubach JP; Hunter ZR; Salman Z; Li J; Cheng M; Clow F; Graef T; Palomba ML; Advani RH
    N Engl J Med; 2015 Apr; 372(15):1430-40. PubMed ID: 25853747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ibrutinib for the treatment of Waldenström macroglobulinemia.
    Chakraborty R; Kapoor P; Ansell SM; Gertz MA
    Expert Rev Hematol; 2015 Oct; 8(5):569-79. PubMed ID: 26138997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia.
    Argyropoulos KV; Palomba ML
    Hematol Oncol Clin North Am; 2018 Oct; 32(5):853-864. PubMed ID: 30190023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ibrutinib (IMBRUVICA°) and Waldenström's macroglobulinaemia.
    Prescrire Int; 2016 Oct; 25(175):232. PubMed ID: 30645823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemia.
    Castillo JJ; Gustine JN; Meid K; Dubeau T; Severns P; Treon SP
    Haematologica; 2018 Jul; 103(7):e307-e310. PubMed ID: 29472352
    [No Abstract]   [Full Text] [Related]  

  • 11. Ibrutinib for the treatment of Bing-Neel syndrome, a complication of Waldenström macroglobulinemia: Patient case report.
    Hartsell L; Janes A; Larck C; Park S; Arnall JR
    J Oncol Pharm Pract; 2019 Sep; 25(6):1534-1539. PubMed ID: 30760164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ibrutinib-induced acute liver failure.
    Kahn A; Horsley-Silva JL; Lam-Himlin DM; Reeder CB; Douglas DD; Carey EJ
    Leuk Lymphoma; 2018 Feb; 59(2):512-514. PubMed ID: 28693376
    [No Abstract]   [Full Text] [Related]  

  • 13. A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia.
    Tam CS; LeBlond V; Novotny W; Owen RG; Tedeschi A; Atwal S; Cohen A; Huang J; Buske C
    Future Oncol; 2018 Sep; 14(22):2229-2237. PubMed ID: 29869556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes.
    Abeykoon JP; Zanwar S; Ansell SM; Gertz MA; Kumar S; Manske M; Novak AJ; King R; Greipp P; Go R; Inwards D; Muchtar E; Habermann T; Witzig TE; Thompson CA; Dingli D; Lacy MQ; Leung N; Dispenzieri A; Gonsalves W; Warsame R; Kyle RA; Rajkumar V; Parikh SA; Kapoor P
    Br J Haematol; 2020 Feb; 188(3):394-403. PubMed ID: 31468508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MYD88 Mutations and Response to Ibrutinib in Waldenström's Macroglobulinemia.
    Treon SP; Xu L; Hunter Z
    N Engl J Med; 2015 Aug; 373(6):584-6. PubMed ID: 26244327
    [No Abstract]   [Full Text] [Related]  

  • 16.
    Gustine JN; Xu L; Tsakmaklis N; Demos MG; Kofides A; Chen JG; Liu X; Munshi M; Guerrera ML; Chan GG; Patterson CJ; Keezer A; Meid K; Dubeau T; Yang G; Hunter ZR; Treon SP; Castillo JJ
    Blood Adv; 2019 Oct; 3(19):2800-2803. PubMed ID: 31570491
    [No Abstract]   [Full Text] [Related]  

  • 17. Ibrutinib therapy for lymphoplasmacytic lymphoma.
    Helber MJ; Moore JE; Williams AM; Meacham PJ; Rothberg PG; Zent CS
    Am J Hematol; 2017 Sep; 92(9):E542-E544. PubMed ID: 28543765
    [No Abstract]   [Full Text] [Related]  

  • 18. [Ibrutinib prescription in B-cell lymphoid neoplasms].
    Dougé A; Ravinet A; Bay JO; Tournilhac O; Guièze R; Lemal R
    Bull Cancer; 2016 Feb; 103(2):127-37. PubMed ID: 26822906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab and ibrutinib in the treatment of Waldenström's macroglobulinemia.
    Grunenberg A; Buske C
    Future Oncol; 2019 Aug; 15(23):2687-2697. PubMed ID: 31184501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review.
    Castillo JJ; Moreno DF; Arbelaez MI; Hunter ZR; Treon SP
    Expert Rev Hematol; 2019 Oct; 12(10):873-881. PubMed ID: 31343930
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.